Inozyme Pharma, Inc.

NasdaqGS INZY

Inozyme Pharma, Inc. Total Assets for the quarter ending September 30, 2024

Inozyme Pharma, Inc. Total Assets is NA for the quarter ending September 30, 2024. Total assets are the total value of all assets owned by a company, representing its resources.

Inozyme Pharma, Inc. Total Assets for the quarter ending September 30, 2023 was USD 205.70 M, a 33.55% change year over year.
Inozyme Pharma, Inc. Total Assets for the quarter ending September 30, 2022 was USD 154.02 M, a 11.82% change year over year.
Inozyme Pharma, Inc. Total Assets for the quarter ending September 30, 2021 was USD 137.75 M.

Key data

Date	Total Assets	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity

NasdaqGS: INZY

Inozyme Pharma, Inc.

CEO	Dr. Douglas A. Treco Ph.D.
IPO Date	July 24, 2020
Location	United States
Headquarters	321 Summer Street
Employees	59
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years